Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0781
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2626
    +0.0004 (+0.03%)
     
  • USD/JPY

    151.3470
    -0.0250 (-0.02%)
     
  • Bitcoin USD

    69,954.89
    -613.46 (-0.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with Dyskinesia

Stock Monitor: Galectin Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Adamas Pharma, Inc. (NASDAQ: ADMS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMS as the Company's latest news hit the wire. On April 18, 2018, the Company announced positive data from the completed Phase-3 open-label trial, EASE LID 2, assessing GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. The results will be presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders (MDS) in Hong Kong, China. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Galectin Therapeutics, Inc. (NASDAQ: GALT), which also belongs to the Healthcare sector as the Company Adamas Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=GALT

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Adamas Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ADMS

EASE LID 2 Study

The EASE LID 2 study is a two-year Phase-3 open-label study of GOCOVRI in 223 Parkinson's disease patients with dyskinesia on levodopa-based therapy. The study enrolled patients from the three GOCOVRI placebo-controlled dyskinesia efficacy trials (EASED, EASE LID, and EASE LID 3) as well as Parkinson's disease patients with dyskinesia who have undergone deep brain stimulation (DBS) treatment. The primary objective of the study was to characterize the long-term safety and tolerability of GOCOVRI dosed once-daily at bedtime for the treatment of dyskinesia in patients with Parkinson's disease.

Patients Receiving GOCOVRI Experienced Long-Term Durability for up to Two Years

Results demonstrated that GOCOVRI was generally well tolerated and the treatment effect on motor complications (dyskinesia and OFF), as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part IV, was maintained for up to two years. This effect was seen in all subgroups, including those switched to GOCOVRI from placebo or amantadine immediate release (IR), as well as a subgroup of patients with uncontrollable dyskinesia after deep brain stimulation (DBS). The safety data are consistent with the previously reported safety profile of GOCOVRI, which includes precautions and warnings related to suicidality, hallucinations, dizziness and orthostatic hypotension.

This final analysis extends and confirms the previously reported results from the 64-week interim analysis published in the Journal of Parkinson's Disease in 2017.

Adamas Commercially Launched GOCOVRI for Treatment of Dyskinesia in Parkinson's Disease Patients

In January 2018, Adamas commercially launched GOCOVRI extended release capsules, for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI was approved by the US Food and Drug Administration (FDA) in August 2017, when it was granted seven years of orphan drug exclusivity, and has been available for physician and patient use since October 2017.

About GOCOVRI

Adamas' lead candidate, GOCOVRI (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI capsules delivers high levels of amantadine upon waking and throughout the day. Data from two pivotal, placebo-controlled clinical studies in 200 patients demonstrated statistically significant reduction in dyskinesia as well as a secondary benefit in OFF time in patients dosed with GOCOVRI.

About Adamas Pharmaceuticals, Inc.

Founded in 2002 and headquartered in Emeryville, California, Adamas Pharma seeks to redefine the treatment experience for patients suffering from chronic neurological diseases. The Company's goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology.

Stock Performance Snapshot

April 20, 2018 - At Friday's closing bell, Adamas Pharma's stock advanced 1.52%, ending the trading session at $28.09.

Volume traded for the day: 958.72 thousand shares.

Stock performance in the last month – up 8.88%; previous six-month period – up 46.00%; and past twelve-month period – up 79.83%

After last Friday's close, Adamas Pharma's market cap was at $692.98 million.

The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Advertisement